Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 15,654 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: BCAA Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin

NCT00757588
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, 5 mg + insulin, Placebo + insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 78 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
16
States / cities
Tempe, Arizona • Fresno, California • Lomita, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 27, 2026, 1:14 PM EDT
Completed Phase 1 Interventional

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT01503242
View directory record Official record
Conditions
Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation, Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
Procedure · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 27, 2026, 1:14 PM EDT
Terminated Phase 2 Interventional

Nesiritide in Chronic Heart Failure

NCT00145873
View directory record Official record
Conditions
Heart Failure
Interventions
nesiritide, continuous infusion
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 27, 2026, 1:14 PM EDT
Completed No phase listed Observational

Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND

NCT00161720
View directory record Official record
Conditions
Protein C Deficiency
Interventions
Protein C Concentrate (Human) Vapor Heated
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Fort Carson, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 27, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa

NCT01538862
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
Granulocyte Colony Stimulating Factor (GCSF)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 27, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer

NCT00857246
View directory record Official record
Conditions
Gastric Cancer, Stomach Cancer
Interventions
Cetuximab, Irinotecan, Cisplatin, Surgery, 5-FU, Radiation
Drug · Procedure · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 27, 2026, 1:14 PM EDT
Not yet recruiting Phase 2 Interventional

T4/T3 Therapy in Hypothyroidism

NCT07424183
View directory record Official record
Conditions
Hypothyroidism Primary
Interventions
Liothyronine (L-T3), Levothyroxine Sodium (LT4) Tablets, Liothyronine (LT3) placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 27, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)

NCT03932240
View directory record Official record
Conditions
Hemostasis
Interventions
Fibrinogen Concentrate (FC), Cryoprecipitate
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Day to 30 Days
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 27, 2026, 1:14 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

NCT01779050
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 27, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

NCT00343291
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cetuximab, Bevacizumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
43
States / cities
Decatur, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 27, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

NCT01705574
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
41
States / cities
Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 27, 2026, 1:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

NCT00667420
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Interventions
panitumumab, epirubicin, oxaliplatin, xeloda
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 27, 2026, 1:14 PM EDT
Terminated Phase 2 Interventional Results available

X-82 to Treat Age-related Macular Degeneration

NCT02348359
View directory record Official record
Conditions
Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD, Macular Degeneration, Age-related, 10, Eye Diseases, Retinal Degeneration, Retinal Diseases
Interventions
X-82, Anti-VEGF, Placebo
Drug
Lead sponsor
Tyrogenex
Industry
Eligibility
50 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
35
States / cities
Tucson, Arizona • Beverly Hills, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 27, 2026, 1:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Dietary Restriction of Animal Protein and Fat on Osteoarthritis

NCT01939262
View directory record Official record
Conditions
Osteoarthritis
Interventions
Limitation of Animal Fat and Protein in the Diet, Control
Other
Lead sponsor
Essentia Health
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Traverse City, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 27, 2026, 1:14 PM EDT
Completed Phase 2 Interventional

Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer

NCT00063388
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Cetuximab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
8
States / cities
Aventura, Florida • Miami Beach, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2010 · Synced Oct 27, 2026, 1:14 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

GnRH Agonist at Embryo Transfer: IVF Outcomes

NCT03544073
View directory record Official record
Conditions
Infertility, Infertility, Female, Infertility, Male
Interventions
Saline Solution for Injection, Leuprolide Acetate
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 27, 2026, 1:14 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab

NCT02130973
View directory record Official record
Conditions
Osteoporosis
Interventions
Standard Clinical Practice Regimen, Experimental Cyclic Regimen
Drug
Lead sponsor
Health Research, Inc.
Other
Eligibility
45 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 27, 2026, 1:14 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Angiotensin II in Liver Transplantation

NCT04901169
View directory record Official record
Conditions
Liver Transplant; Complications, Vasoplegia
Interventions
Angiotensin II, Saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 27, 2026, 1:14 PM EDT
Completed Phase 4 Interventional Results available

Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia

NCT00140413
View directory record Official record
Conditions
Growth Hormone Deficiency, Septo-Optic Dysplasia, Hypopituitarism
Interventions
Nutropin AQ
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 5 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 27, 2026, 1:14 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure

NCT00001962
View directory record Official record
Conditions
Aplastic Anemia, Pure Red Cell Aplasia, Diamond Blackfan Anemia
Interventions
Daclizumab
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 27, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT00738062
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
44
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 27, 2026, 1:14 PM EDT
Completed Phase 4 Interventional Results available

MENOPUR® Versus FOLLISTIM®

NCT00802360
View directory record Official record
Conditions
Infertility
Interventions
Menotropin, Progestrone vaginal insert, follitropin beta, Progesterone in oil, Ganirelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Pasadena, California • San Diego, California • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 27, 2026, 1:14 PM EDT
Terminated Phase 2 Interventional Results available

Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

NCT00866723
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Serous Cancer, Fallopian Tube Cancer
Interventions
bevacizumab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 27, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Study of Ramucirumab in Ovarian Cancer

NCT00721162
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Ramucirumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
11
States / cities
Hollywood, Florida • Orlando, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 27, 2026, 1:14 PM EDT